Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis

Cancer Research

Volumn 60, Issue 16, 2000, Pages 4446-4452

  Jenne, Lars ^a   Arrighi, Jean François ^a   Jonuleit, Helmut ^b   Saurat, Jean Hilaire ^a   Hauser, Conrad ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOPHENOL MONOOXYGENASE; PEPTIDE; PROSTAGLANDIN E2; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIGEN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER; CANCER CONTROL; CANCER IMMUNOTHERAPY; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TUMOR CELL LINE;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MELANOMA; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PHAGOCYTOSIS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034662641     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Genes coding for tumor antigens recognized by cytolytic T lymphocytes
2. Tumor antigens recognized by T lymphocytes
3. Cancer antigens: Immune recognition of self and altered self
4. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes
5. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen
6. New insights into the mobilization and phagocytic activity of dendritic cells
7. Ceramide inhibits antigen uptake and presentation by dendritic cells
8. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions
9. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides
10. A Phase 1 study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
11. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
12. Rapid extracellular degradation of synthetic class 1 peptides by human dendritic cells
13. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3
14. Cross-presentation: A general mechanism for CTL immunity and tolerance
15. The selective engulfment of apoptotic bodies by dendritic cells is mediated by the α(v)β3 integrin and requires intracellular and extracellular calcium
16. Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
17. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
18. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells
19. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α
20. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues
21. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes
22. Simultaneous analysis of immunophenotype and apoptosis of murine thymocytes by single laser flow cytometry
23. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes
24. Expression of HLA class I antigens in transporter associated with antigen processing (TAP)-deficient mutant cell lines
25. Consequences of cell death. Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
26. Natural adjuvants: Endogenous activators of dendritic cells
27. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay
28. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: Conditions, efficiency, and relation to antibody responses
29. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help
30. Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer
31. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy
32. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy
33. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
34. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin
35. The central role of CD4(+) T cells in the antitumor immune response
36. Immunotherapy of cancer with dendritic-cell-based vaccines